The Difference Between Life and Living:
Physician Insights on CINV Prevention
MEET THE SPEAKER
Alex A. Ehsan, MD, PhD
The Oncology Institute of Hope and Innovation
Dr. Ehsan is a board-certified oncologist and researcher at The Oncology Institute of Hope and Innovation with extensive experience in developing patient-centered care strategies for cancer therapy. In this webinar, he shares his perspective on optimizing CINV prevention to improve patient quality of life and treatment adherence.
What Is Sancuso® (Granisetron Transdermal System)?
Sancuso is the first and only FDA-approved transdermal system that delivers granisetron for the prevention of nausea and vomiting in patients receiving moderately and highly emetogenic chemotherapy. The patch provides up to seven days of continuous relief, helping patients maintain their chemotherapy regimens without interruption.1
Sancuso is a serotonin-3 (5-HT3) receptor antagonist indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days. Sancuso® is contraindicated in patients with hypersensitivity to granisetron or adhesives. Common adverse reactions: constipation and headache. Serotonin syndrome risk with other serotonergic drugs.
See full prescribing information at sancuso.com.
References:
1. Sancuso [package insert]. Nashville, TN. Cumberland, Inc.; 2024
WWW1501125